File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis

TitleA Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Authors
Singh, GHHYacoub, APettit, KMBradley, TGerds, ATTatarczuch, MShortt, JCurtin, NJRossetti, JMBurbury, KMead, AJGöthert, JRKoschmieder, SJones, APeppe, JNatsoulis, GHong, WJStevenson, WSEwing, JHarrison, CNVannucchi, AWatts, JRoss, DMTalpaz, MRienhoff, HY
Issue Date2021
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
2021 American Society of Hematology (ASH) 63rd Meeting & Exposition, Atlanta, Georgia, USA, 10-14 December 2021. In Blood, v. 138 n. Suppl. 1, abstract no. 139 How to Cite?
DOI: http://dx.doi.org/10.1182/blood-2021-148682
DescriptionOral Abstract - Session 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Persistent Identifierhttp://hdl.handle.net/10722/309389
ISSN
0006-4971
2023 Impact Factor: 21.0
2023 SCImago Journal Rankings: 5.272
ISI Accession Number ID
WOS:000736398800137

 

DC FieldValueLanguage
dc.contributor.authorSingh, GHH-
dc.contributor.authorYacoub, A-
dc.contributor.authorPettit, KM-
dc.contributor.authorBradley, T-
dc.contributor.authorGerds, AT-
dc.contributor.authorTatarczuch, M-
dc.contributor.authorShortt, J-
dc.contributor.authorCurtin, NJ-
dc.contributor.authorRossetti, JM-
dc.contributor.authorBurbury, K-
dc.contributor.authorMead, AJ-
dc.contributor.authorGöthert, JR-
dc.contributor.authorKoschmieder, S-
dc.contributor.authorJones, A-
dc.contributor.authorPeppe, J-
dc.contributor.authorNatsoulis, G-
dc.contributor.authorHong, WJ-
dc.contributor.authorStevenson, WS-
dc.contributor.authorEwing, J-
dc.contributor.authorHarrison, CN-
dc.contributor.authorVannucchi, A-
dc.contributor.authorWatts, J-
dc.contributor.authorRoss, DM-
dc.contributor.authorTalpaz, M-
dc.contributor.authorRienhoff, HY-
dc.date.accessioned2021-12-29T02:14:25Z-
dc.date.available2021-12-29T02:14:25Z-
dc.date.issued2021-
dc.identifier.citation2021 American Society of Hematology (ASH) 63rd Meeting & Exposition, Atlanta, Georgia, USA, 10-14 December 2021. In Blood, v. 138 n. Suppl. 1, abstract no. 139-
dc.identifier.issn0006-4971-
dc.identifier.urihttp://hdl.handle.net/10722/309389-
dc.descriptionOral Abstract - Session 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis-
dc.languageeng-
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/-
dc.relation.ispartofBlood-
dc.relation.ispartof2021 American Society of Hematology (ASH) 63rd Meeting & Exposition-
dc.titleA Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis-
dc.typeConference_Paper-
dc.identifier.emailSingh, GHH: gillhsh@hku.hk-
dc.identifier.authoritySingh, GHH=rp01914-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1182/blood-2021-148682-
dc.identifier.hkuros331293-
dc.identifier.volume138-
dc.identifier.issueSuppl. 1-
dc.identifier.spage139-
dc.identifier.epage139-
dc.identifier.isiWOS:000736398800137-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats